Rockland Immunochemicals Acquires Epi-Plus® Product Line
News Apr 09, 2013
Epi-Plus® antibodies are widely regarded as the most well validated antibodies available for epigenetics research. All Epi-Plus® antibodies are multi-assay validated, including dot blot testing using modified peptide arrays, western blots, and chromatin immunoprecipitation (ChIP).
Current research in Epigenetics, the study of changes in gene expression or cellular phenotype, has shown that epigenetic pharmaceuticals could be a putative replacement or adjuvant therapy for currently accepted treatment methods such as radiation and chemotherapy. The global revenue market for epigenetics has been estimated at $2.6 Billion in 2012 and is expected to reach $8 Billion by 2017, a five-year CAGR of 25%.
"The acquisition of the Epi-Plus® product line expands Rockland’s Life Science Tools portfolio and will allow our customers to perform their research in a more efficient and effective manner, ultimately saving time and precious research dollars," commented Jim Fendrick, President and CEO of Rockland Immunochemicals. “The fact that the Epi-Plus® brand is co-owned by Novus Biologicals also allows us to expand the Rockland brand globally."
“As 21st Century Biochemicals continues to focus its efforts on providing US manufactured custom peptide and antibody solutions for its customers, we are pleased that the Epi-Plus® product line is a strong strategic fit for the Rockland portfolio,” added Dr. Jordan Fishman, President and CSO of 21st Century Biochemicals.
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.
Epigenetic Drug Against Mantle Cell LymphomaNews
A new study presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL), a type of cancer characterized by its aggressive behavior, its delayed diagnosis with affectation of different organs and its origin from the lymphocytes B.READ MORE